Company Analysis
Sign in

Arbutus Biopharma Corporation (ABUS)

Nasdaq: ABUS · Pharmaceutical Preparations · Warminster, PA · filing with the SEC since 2008
Full chart Alerts Compare
Grade4.7
◀ Past 5.6● Present 3.9▶ Future 4.9
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

71 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arbutus Biopharma Corporation’s names, not what it holds today.

Patents granted
71
71 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 8 in 2024 and 5 in 2023
Applications published
130
4 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals20
Organic fine chemistry13
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
ARBUTUS BIOPHARMA CORPORATION its own name
CA, as the owner printed on each patent
57 granted
81 published
Tekmira Pharmaceuticals Corporation a former name
CA, as the owner printed on each patent
14 granted
20 published
ARBUTUS BIOPHARMA CORPORATION its own name
named as the applicant on its applications, in CA
0 granted
25 published
Tekmira Pharmaceuticals Corporation a former name
named as the applicant on its applications, in CA
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,453,776Lipids and compositions for the delivery of therapeuticsOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Jul 15, 202512,357,705Negatively charged peg-lipid conjugatesPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Jul 8, 202512,350,383Cationic lipids containing siliconPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Mar 18, 202512,251,470Lipid nanoparticle formulationsPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Oct 29, 202412,129,467Non-liposomal systems for nucleic acid deliveryPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Sep 10, 202412,083,118Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using sameOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Jul 23, 202412,043,833Targeted compositionsPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Jul 23, 202412,042,541Lipids and compositions for the delivery of therapeuticsOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Jul 2, 202412,023,383Lipid compositionsPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Jun 25, 202412,016,929Lipid formulations for delivery of therapeutic agentsPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 11, 20252025/0281422CATIONIC LIPIDS CONTAINING SILICONPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Jun 5, 20252025/0179496TARGETED COMPOSITIONSPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Mar 27, 20252025/0099594TARGETED COMPOSITIONSOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Jan 30, 20252025/0034571NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERYPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Dec 26, 20242024/0424105NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION · patent 12,453,776 granted from it
Nov 14, 20242024/0374595SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAMEOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Oct 3, 20242024/0327419SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOFOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Sep 26, 20242024/0316206NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTSPharmaceuticalsARBUTUS BIOPHARMA CORPORATION
Jul 25, 20242024/0246964SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAMEOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
Jul 25, 20242024/0245784TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONSOrganic fine chemistryARBUTUS BIOPHARMA CORPORATION
What it applied for, 2024 to 2025: Pharmaceuticals 12 · Organic fine chemistry 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ABUS · research, not advice